Steglatro 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
IAIN/0016/G 
This was an application for a group of variations. 
05/12/2022 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
amended 
on 
Annex II and 
PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
Not including batch control/testing 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
A.5.a - Administrative change - Change in the name 
and/or address of a manufacturer/importer 
responsible for batch release 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
R/0015 
Renewal of the marketing authorisation. 
15/09/2022 
15/11/2022 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Steglatro in the approved indication remains favourable and 
therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
PSUSA/10682
Periodic Safety Update EU Single assessment - 
01/09/2022 
n/a 
PRAC Recommendation - maintenance 
/202112 
ertugliflozin 
WS/1953 
This was an application for a variation following a 
16/09/2021 
22/10/2021 
SmPC and PL 
Please refer to Scientific Discussion Steglatro and 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
Update of sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the 
SmPC of Steglatro and Segluromet in order to modify 
the indication, update posology recommendations 
and include efficacy and safety information based on 
Segluromet EMEA/H/C/WS1953 
Page 2/5 
 
 
 
 
 
 
 
 
 
 
final results from the VERTIS CV study (protocol 
8835-004/B1521021) listed as a category 3 study in 
the RMP. This is a multi-centre, multi-national, 
randomised, double-blind, placebo-controlled study 
to evaluate the effect of ertugliflozin on 
cardiovascular risk in adult patients with type 2 
diabetes and established atherosclerotic 
cardiovascular disease. The Package Leaflet is 
updated accordingly. 
C.I.6.a - Change(s) to therapeutic indication(s) - 
Addition of a new therapeutic indication or 
modification of an approved one 
WS/1825 
This was an application for a variation following a 
23/07/2020 
09/07/2021 
SmPC and PL 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
PSUSA/10682
Periodic Safety Update EU Single assessment - 
09/07/2020 
n/a 
PRAC Recommendation - maintenance 
/201912 
ertugliflozin 
IB/0011 
B.I.b.1.h - Change in the specification parameters 
16/04/2020 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition or 
replacement (excl. Biol. or immunol. substance) of a 
specification parameter as a result of a safety or 
quality issue 
Page 3/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IG/1211 
B.I.a.3.a - Change in batch size (including batch size 
27/02/2020 
n/a 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
PSUSA/10682
Periodic Safety Update EU Single assessment - 
16/01/2020 
n/a 
PRAC Recommendation - maintenance 
/201906 
ertugliflozin 
IG/1157 
C.I.z - Changes (Safety/Efficacy) of Human and 
14/11/2019 
12/05/2020 
SmPC, Annex 
Veterinary Medicinal Products - Other variation 
II, Labelling 
and PL 
PSUSA/10682
Periodic Safety Update EU Single assessment - 
11/07/2019 
n/a 
PRAC Recommendation - maintenance 
/201812 
ertugliflozin 
WS/1590 
This was an application for a variation following a 
23/05/2019 
12/05/2020 
SmPC and PL 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
PSUSA/10682
Periodic Safety Update EU Single assessment - 
31/01/2019 
02/04/2019 
Refer to Scientific conclusions and grounds recommending 
/201806 
ertugliflozin 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10682/201806. 
WS/1488 
This was an application for a variation following a 
14/02/2019 
n/a 
No changes to the product information are warranted at 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
Submission of the final CSR for Study P007/1017 - a 
Phase 3, randomized, double-blind, placebo-
present. The RMP will be updated at the next opportunity. 
The benefit/risk ration for Steglatro, Steglujan and 
Segluromet is unchanged. 
Page 4/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
controlled, 26-week multicenter study with a 78-
week extension to evaluate the efficacy and safety of 
ertugliflozin in subjects with type 2 Diabetes Mellitus 
and inadequate glycaemic control on metformin 
monotherapy - together with the final summarized 
data of all adjudicated confirmed fractures from the 
broad pool and pooled 2-year safety data from the 7 
completed Phase 3 studies, including both 2-year 
studies P007/1017 and P002/1013. 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
T/0002 
Transfer of Marketing Authorisation 
12/07/2018 
28/08/2018 
SmPC, 
Labelling and 
PL 
IB/0001/G 
This was an application for a group of variations. 
26/04/2018 
28/08/2018 
SmPC, 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
Labelling and 
PL 
Page 5/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
